USE OF REGULARLY SCHEDULED HIGH DOSE INTRAVENOUS METHOTREXATE THERAPY, WITH INTERIM ADMINISTRATION OF IMMUNOMODULATORY AGENTS, TO TREAT MULTIPLE SCLEROSIS AND OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM
Patent 6903100 Issued on June 7, 2005. Estimated Expiration Date: 
April 24, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 24, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethotrexate compositions and methods of treatment using same Treatment of autoimmune disease using tolerization in combination with methotrexate Patent #: 5935577 InventorAssigneeApplicationNo. 10128947 filed on 04/24/2002US Classes:514/251, Isoalloxazine (e.g., riboflavins, Vitamin B2, etc.)514/186, Bicyclo ring system514/521, C=O other than as ketone or aldehyde514/638, Nitrogen double bonded directly to carbon514/742, Polynitro424/184.1, ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)424/279.1Synthetic or structurally-modified peptidoglycan or mucopolysaccharide or fragment thereof (e.g., derivative of N-acetyl-muramyl-L-alanyl-D-glutamic or fragment thereof (e.g., derivative of N-acetyl-muramyl-L-alanyl-D- acid, etc.) glutamic acid, etc.)ExaminersPrimary: Henley, III, RaymondAttorney, Agent or FirmInternational ClassesA61K031/525A61K031/555 A61K031/275 A61K039/38 A61K045/00 AbstractThe present invention is directed to the treatment of multiple sclerosis by periodically administering a high dose of methotrexate at a level sufficiently high to cross the blood brain barrier. The methotrexate administration is accompanied by leucovorin rescue of the periphery. The high dose methotrexate is preferably administered at 1 to 4 month intervals. The periodic high dose methotrexate treatment may be used in conjunction with interim treatments using a therapeutic agent that is effective in treating MS, but does not cross the BBB in cytotoxic amounts. It is contemplated that the method of the present invention may be employed to treat other non-infectious, non-neoplastic inflammatory conditions of the CNS.Other References
Field of SearchIsoalloxazine (e.g., riboflavins, Vitamin B2, etc.)Bicyclo ring system C=O other than as ketone or aldehyde MULTIPLE SCLEROSIS INTERFERON INDUCER Nitrogen double bonded directly to carbon Polynitro ARTHRITIS ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.) INVOLVING AUTOIMMUNITY, ALLERGY, IMMEDIATE HYPERSENSITIVITY, DELAYED HYPERSENSITIVITY, IMMUNOSUPPRESSION, IMMUNOTOLERANCE, OR ANERGY Synthetic or structurally-modified peptidoglycan or mucopolysaccharide or fragment thereof (e.g., derivative of N-acetyl-muramyl-L-alanyl-D-glutamic or fragment thereof (e.g., derivative of N-acetyl-muramyl-L-alanyl-D- acid, etc.) glutamic acid, etc.) | |
